Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page Small font size Default font size Increase font size Users Online: 101
ORIGINAL ARTICLE
Year : 2015  |  Volume : 16  |  Issue : 1  |  Page : 17-22

Narrow-band ultraviolet B in childhood vitiligo: An open prospective uncontrolled study in 28 children of South India


1 Department of Dermatology, Raja Rajeswari Medical College and Hospital, Kambipura, Bengaluru, Karnataka, India
2 Department of Dermatology, GSL Medical College and General Hospital, Rajahmundry; Departments of Dermatology, Surya Skin Care and Research Centre, Visakhapatnam, Andhra Pradesh, India

Correspondence Address:
G Raghurama Rao
Surya Skin Care and Research Centre, Naoroji Road, Maharanipeta, Visakhaptanam, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2319-7250.149424

Rights and Permissions

Background: Management of vitiligo in children is difficult as therapeutic options are restricted when compared to that in adult patients. Selection of treatment should be careful in these patients with the aim to achieve best results with minimal side effects. Only few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in children with vitiligo. Aims: The purpose of this study was to know the efficacy and safety of NBUVB in children with vitiligo of age group ranging from 3 to 16 years. Methods: Twenty-eight patients (12 males, 16 females), aged 3-16 years with vitiligo were included in the study between years 2011 and 2013 and were treated twice weekly with NBUVB. The starting dose was 150 mJ/cm 2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1-year and were followed-up for another 12 months for stability of repigmentation. Results: Analysis of our study showed that a majority of our cases, 22 (78.6%) had > 75% to complete repigmentation, about 4 (14.2%) achieved 26-75% moderate repigmentation and 2 (7.2%) had < 25% mild repigmentation. Adverse effects were transient and minimal. Only one child developed depigmentation of repigmented sites during 1-year follow-up. Conclusion: Our study proves that NBUVB therapy is safe and effective tool in the management of childhood vitiligo, with good stability of repigmentation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5663    
    Printed65    
    Emailed1    
    PDF Downloaded437    
    Comments [Add]    
    Cited by others 2    

Recommend this journal